nadunolimab + mFOLFOX

Nadu­nolimab + mFOLFOX is an investigational combination regimen comprising nadunolimab, a human monoclonal antibody targeting Interleukin-1 Receptor Accessory Protein (IL1RAP), and mFOLFOX, a modified standard-of-care chemotherapy regimen. - Nadunolimab (CAN04) inhibits IL1RAP, thereby blocking IL-1 mediated pro-inflammatory signaling critical for tumor progression and the tumor microenvironment. - mFOLFOX is a chemotherapy regimen that combines folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. These agents exert cytotoxic effects by interfering with DNA synthesis and repair in dividing tumor cells. This combination has shown early evidence of anti-tumor activity and a potential to reduce chemotherapy-induced peripheral neuropathy (CIPN), representing a possible dual benefit for patients, particularly in advanced pancreatic ductal adenocarcinoma (PDAC) and potentially other solid tumors. Clinical development is ongoing to validate efficacy and neuroprotection[1][7].

Other names

CAN04 + mFOLFOXnadunolimab + FOLFOX